Inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells and application thereof

Abstract

The embodiment relates to modified cells for treating a solid tumor, a composition and a method. For example, the composition comprises inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells; the modified cells comprise separated polynucleotide; and the separated polynucleotide comprises polynucleotide of coded FLT3L and polynucleotide of a coded Nuclear Factor of Activated T cells (NFAT) promoter, which is operably connected.

Description

technical field [0001] The present disclosure relates to inducible Fms-related tyrosine kinase 3 ligand-modified cells and uses thereof to treat diseases including cancer. Background technique [0002] With the rapid development of CAR-T technology, CAR-T products targeting tumor-associated antigens (TAA) have been continuously produced. CAR-T cells can accurately target tumor cells, migrate to tumor sites, and be activated by tumor antigens to kill tumor cells. However, CAR-T cells still face challenges in the treatment of solid tumors. Currently, genome editing technologies are able to disrupt gene expression in T cells to enhance effector functions or bypass tumor immunosuppression and metabolically unfavorable tumor microenvironments. Therefore, regulatory T cells are required to address problems associated with solid tumors. Contents of the invention [0003] 1. The problem to be solved [0004] Aiming at the absence of obvious inflammatory response activation in ...

AI Technical Summary

Problems solved by technology

But CAR-T cells still face chal

Images